HOME >> BIOLOGY >> NEWS
Epimmune scientists report positive pre-clinical data on vaccine designed to combat HIV's ability to mutate

Company on track to initiate clinical trials late this year or early 2002 of epitope-based vaccine for the prevention and treatment of HIV

Keystone, CO, April 2, 2001 - Epimmune Inc. (Nasdaq: EPMN) today announced positive pre-clinical data on its HIV vaccine that is designed to directly address the problem of viral mutation. At the Keystone Symposium: "AIDS Vaccines in the New Millennium" on March 30, 2001 in Keystone, Colorado, Company scientists reported that the vaccine stimulated multiple anti-HIV cytotoxic T-cell immune responses in animal models. Epimmune has begun manufacturing the vaccine for human testing and plans to initiate clinical trials late this year or early 2002 in both non-infected volunteers and in individuals infected with HIV.

The current standard HIV therapy for Americans is a three-drug anti-retroviral combination that costs approximately $15,000 per year. While anti-retroviral drugs are effective at suppressing HIV replication in infected individuals, they do not eliminate the infection and have toxic side effects that impede their long-term use. A vaccine that can provide both preventative and therapeutic benefits has great potential to help control the AIDS epidemic and curtail the costs and side effects of anti-retroviral therapies.

"A major challenge to the development of an effective AIDS vaccine is the ability of HIV to mutate. Epimmunes vaccine is designed to directly address this problem," said Mark Newman, Ph.D., Vice President of the Infectious Disease Program at Epimmune. "One of the unique features of Epimmunes vaccine is that it is composed of epitopes, or protein fragments, which are strategically selected from non-mutating regions of HIV. As a result, it is expected to be harder for the virus to develop variants that can escape the vaccine-induced immune response."

Strong cellular immunity is characteristic of long-term non-progressors or HIV-positive individuals
'"/>

Contact: Laura Hansen
lhansen@irpr.com
858-860-0266
Epimmune, Inc.
1-Apr-2001


Page: 1 2

Related biology news :

1. DNA lends scientists a hand, revealing new chemical reactions
2. Conference at UH opens doors for new scientists, engineers
3. Wisconsin scientists develop quick botox test
4. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
5. Alaska scientists find Arctic tundra yields surprising carbon loss
6. UAF scientists discover new marine habitat in Alaska
7. Information system to help scientists analyze mechanisms of social behavior
8. Zoonotic diseases - European scientists unite to fight diseases
9. Israeli scientists reveal the plan of a key cellular machine
10. Study by Israeli scientists provides insight on DNA code
11. Computer scientists at UH developing nurturing computers

Post Your Comments:
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/16/2015)... 16, 2015 Between 16 ... present groundbreaking innovations in biometric identification at the ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... is well at the forefront: the company,s all ... in Germany . BiometricGate is ...
(Date:3/12/2015)... Beta Systems today announced ... management (IAM) solution for a fixed price and ... new IAM package, customers benefit from the 30 ... IAM implementations across different industries. The new fixed-price ... any necessary services and consulting. It spans the ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
(Date:3/25/2015)... 26, 2015 Agnition announced today that ... American Farmer, airing for the first time at 7:30 ... American Farmer will explore the extremely important role soil ... with a patented Microbial Catalystâ„¢ technology that enhances soil ... The segment will air again on April 28. , ...
(Date:3/25/2015)... 2015 Optimal Research, LLC has been nominated ... Award "Best Clinical Site or Trial Network". ... been selected as a nominee in this ViE award ... Recommended" distinction in 2014. The ViE awards were created ... and positive contributions of companies and individuals in the ...
(Date:3/25/2015)... 2015  S&P Capital IQ (MHFI) announced today ... coverage on Abattis Bioceuticals Corp . ... a specialty biotechnology company with capabilities through its ... proprietary ingredients, bio-similar compounds, patented equipment and consulting ... America . The company seeks to capitalize ...
(Date:3/25/2015)... 25, 2015 Accelovance, a therapeutically focused contract ... "Best Contract Research Organization" at the upcoming Vaccine Industry ... This is the eighth consecutive year ... award, winning for "Best Contract Research Organization" in 2009, ... in 2013. "We,re excited to be a ...
Breaking Biology Technology:Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2
Cached News: